FeaturedApril 10, 2026 · Clinical Research
Semaglutide Reduces Cardiovascular Risk by 20% in Landmark SELECT Trial
The SELECT trial involving 17,604 overweight adults demonstrated that weekly semaglutide injections significantly reduced major adverse cardiovascular events, establishing GLP-1 receptor agonists as a cornerstone of cardiometabolic therapy.
Read full study